Kendra Goldhirsch is an Associate at the Firm. Ms. Goldhirsch is a 2015 New York Metro Super Lawyers Rising Star. Her practice focuses on national product liability litigation and mass torts.
On April 22, 2016, a couple from Illinois filed an Invokana lawsuit in the District of New Jersey, Trenton Division. They named manufacturers Janssen Pharmaceuticals and parent company Johnson & Johnson (J&J) as defendants. This is one of many cases that have been filed concerning…
After May 19, 2016, plaintiffs will no longer be able to file joint complaints in the Xarelto MDL currently proceeding in the Eastern District of Louisiana. After that, only individual complaints will be allowed. All federal Xarelto lawsuits were consolidated there in December 2014, and…
The number of lawsuits filed against diabetes drug Invokana manufacturer Janssen Pharmaceuticals (and parent company Johnson & Johnson) continues to increase. On March 31, 2016, a new case was filed in the Superior Court of the State of Delaware. The plaintiff, a Tennessee resident, claims…
In December 2014, all federally filed Xarelto lawsuits were consolidated into the Eastern District of Louisiana for pre-trial proceedings. Since then, the court has seen a steady increase in the number of cases there. Another new lawsuit joined the MDL on March 16, 2016. The…
On December 12, 2014, the U.S. Judicial Panel on Multidistrict Litigation consolidated all federally filed Xarelto lawsuits into one court in the Eastern District of Louisiana. Since then, the parties have been involved in choosing potential cases to proceed to early bellwether trials. In a…
In October 2014, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all Cook Medical IVC filter lawsuits into one court, in the Southern District of Indiana. Since then, both sides have been involved in pre-trial proceedings to prepare a small number of cases for…
A California resident has joined in the litigation against type 2 diabetes drug Invokana (canagliflozin). The drug was first approved by the FDA in 2013 for the treatment of the disease, but manufacturers Janssen Pharmaceuticals and parent company Johnson & Johnson have been defending Invokana…
The European Medicines Agency’s (EMA’s) Pharmocovigilance Risk Assessment Committee (PRAC) recently finalized their review of SGLT2 inhibitors—type 2 diabetes drugs including Invokana. They concluded that additional recommendations were needed to help minimize the risk of one potentially dangerous s
Since October 2015, federal Zofran lawsuits have been consolidated in the U.S. District Court for the District of Massachusetts. Just a couple months after consolidation, manufacturer GlaxoSmithKline (GSK) filed a motion to dismiss all of the cases pending in the newly established MDL, “as preempted
On November 13, 2015, a Texas woman filed a new Invokana lawsuit against manufacturers Janssen Pharmaceuticals and parent company Johnson & Johnson (J&J). She blames the defendants for the serious injuries she suffered after taking the type 2 diabetes drug. The case was filed in…
Is the FDA doing enough to protect the public from potentially serious drug side effects? According to a recently released Government Accountability Office (GAO) report, it doesn’t look like it. Though the administration approved many drugs between 2006 and 2014 through their “fast-track” processes,
Reports of problems with type 2 diabetes drug Invokana (canagliflozin) have continued to increase, according to the Institute for Safe Medicine Practices (ISMP) most recent QuarterWatch for the second quarter of 2015. “Both prescription volume and adverse drug event reports are increasing rapidly fo